SCHEMBL579403

SCHEMBL579403

Cc1ccc2c(C(N)=O)cn(F)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K2 P36507 1/20 0.40
MAP2K1 Q02750 1/20 0.40
CNR1 P21554 2/20 0.38
ICMT O60725 1/20 0.38
CNR2 P34972 1/20 0.38
TLR8 Q9NR97 1/20 0.36
PARP1 P09874 1/20 0.36
GRM2 Q14416 3/20 0.35
MAPT P10636 2/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ADRA1D P25100 1/20 0.33
KCNMA1 Q12791 1/20 0.33
NPC1 O15118 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL579775 0.85 CSNK2A1 (0.44) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL579950 0.83 CNR1 (0.39) MAP2K2MAP2K1CNR1ICMTCNR2
SCHEMBL579786 0.81 NR4A2 (0.44) MAP2K2MAP2K1MAPTMEN1KMT2A
SCHEMBL10193361 0.78 CNR1 (0.46) MAP2K2MAP2K1CNR1ICMTCNR2
SCHEMBL784673 0.76 KDM4E (0.44) CNR1MAPTMEN1KMT2AKDM4E
SCHEMBL28131995 0.73 ICMT (0.47) MAP2K2MAP2K1CNR1ICMTMAPT
SCHEMBL10341192 0.73 KDM4E (0.49) MAP2K2MAP2K1MEN1KMT2AKDM4E
SCHEMBL30568918 0.71 IDO1 (0.54) MAP2K2MAP2K1CNR1CNR2MAPT
SCHEMBL9919096 0.71 BRD4 (0.50) MAP2K2MAP2K1MAPTKDM4E
SCHEMBL28131233 0.69 ICMT (0.55) MAP2K2MAP2K1CNR1ICMTCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735414-B2 Indole derivatives and methods for antiviral treatment PTC THERAPEUTICS, INC. (US) 2014-05-27 US disclosed
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC THERAPEUTICS, INC. (US) 2012-07-19 US disclosed
EP-2417122-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC Therapeutics, Inc. (US) 2012-02-15 EP disclosed
WO-2010117932-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT IDO1, IRF3, MAVS MAP2K2 3462/4885MAP2K1 3939/4885CNR1 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.